Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer

Purpose Transforming growth factor-beta inhibitors may enhance the antitumor activity of gemcitabine with acceptable safety and tolerability. This open-label, multicenter, non-randomized phase 1b study assessed the safety/tolerability, pharmacokinetics, and tumor response of galunisertib plus gemcit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2017-06, Vol.79 (6), p.1169-1177
Hauptverfasser:	Ikeda, Masafumi, Takahashi, Hideaki, Kondo, Shunsuke, Lahn, Michael Mauritius Fabio, Ogasawara, Ken, Benhadji, Karim A., Fujii, Hisaki, Ueno, Hideki
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anorexia Anticancer properties Antimetabolites, Antineoplastic - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor activity Area Under Curve Asian Continental Ancestry Group Biomarkers, Tumor - analysis Blood cells CA-19-9 Antigen - analysis Cancer Cancer Research Carbohydrates Cell number Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Disease-Free Survival Female Gemcitabine Humans Hypophosphatemia Incidence Male Maximum Tolerated Dose Medicine Medicine & Public Health Metastases Metastasis Middle Aged Neutrophils Oncology Original Article Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Patients Pharmacokinetics Pharmacology Pharmacology/Toxicology Pyrazoles - administration & dosage Quinolines - administration & dosage Safety Toxicity Transforming growth factor-b
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!